Prostate CarcinomaNCT00540059
Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
An observational study of Prostate Carcinoma, run by AstraZeneca.
Trial summary
Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Prostate Carcinoma
- How many people
- 1,950 participants
- Where
- No sites listed yet
- Study dates
- Jun 2005to not given
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with PCa, who will be treated with Zoladex 10,8 SafeSystem based on the current SPC
Who cannot join
None listed.
About this study
Official title: Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem
Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions
- Conditions
- Prostate Carcinoma
- Keywords
- Prostate carcinoma, LHRH, Zoladex
- Medical subject headings
- Prostatic Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2007 (estimated)
- Study startJun 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CarcinomaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
- Enrolment
- 1,950 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- H Brasch, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00540059
- Sponsor's protocol ID
- Zx-002
- Status last verified
- Aug 2007
- First submitted
- 3 Oct 2007
- Last updated
- 5 Oct 2007
- Results posted
- No